Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Phase 2A, Double-blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety, Tolerability, PD, and PK of HU6 for the Treatment of Subjects With Obese Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT05284617 is registered in ClinicalTrials.gov with Rivus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05284617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05284617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Phase 2A, Double-blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety, Tolerability, PD, and PK of HU6 for the Treatment of Subjects With Obese Heart Failure With Preserved Ejection Fraction (HFpEF)
Lead sponsor
Rivus Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 30, 2022
Completion date
May 30, 2024
Enrollment
67 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction